CoChat

Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells

Published version of a preprint

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

Purpose: Transforming growth factor β (TGFβ) is a pleiotropic cytokine that affects tumor growth, metastasis, stroma, and immune response. We investigated the therapeutic efficacy of anti–TGFβ receptor II (TGFβ RII) antibody in controlling metastasis and tumor growth as well as enhancing antitumor immunity in preclinical tumor models. Experimental Design: We generated neutralizing antibodies to TGFβ RII and assessed the antibody effects on cancer, stroma, and immune cells in vitro. The efficacy and mechanism of action of the antibody as monotherapy and in combination with chemotherapy in suppression of primary tumor growth and metastasis were evaluated in several tumor models. Results: Anti–TGFβ RII antibody blocked TGFβ RII binding to TGFβ 1, 2, and 3, and attenuated the TGFβ-mediated activation of downstream Smad2 kinase, invasion of cancer cells, motility of endothelial and fibroblast cells, and induction of immunosuppressive cells. Treatment with the antibody significantly suppressed primary tumor growth and metastasis and enhanced natural killer and CTL activity in tumor-bearing mice. Immunohistochemistry analysis showed cancer cell apoptosis and massive necrosis, and increased tumor-infiltrating T effector cells and decreased tumor-infiltrating Gr-1+ myeloid cells in the antibody-treated tumors. Fluorescence-activated cell sorting analysis indicated the significant reduction of peripheral Gr-1+/CD11b+ myeloid cells in treated animals. Concomitant treatment with the cytotoxic agent cyclophosphamide resulted in a significantly increased antitumor efficacy against primary tumor growth and metastasis. Conclusions: These preclinical data provide a foundation to support using anti–TGFβ RII antibody as a therapeutic agent for TGFβ RII–dependent cancer with metastatic capacity. Clin Cancer Res; 16(4); 1191–205

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-09-1634

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 49 references

Cited by

See all 123

Metadata

Authors
Zhong, Z., Carroll, K. D., Policarpio, D., Osborn, C., Gregory, M., Bassi, R., Jimenez, X., Prewett, M., Liebisch, G., Persaud, K., Burtrum, D., Wang, S., Surguladze, D., Ng, S., Griffith, H., Balderes, P., Doody, J., Schwartz, J. D., Youssoufian, H., Rowinsky, E. K., Ludwig, D. L., Witte, L., Zhu, Z., & Wu, Y.
Affiliations
Authors' Affiliations: Departments of 1Antibody Technology & Immunology, 2Cell Biology, 3Preclinical Pharmacology, 4Molecule and Cell Engineering, 5Protein Science, 6Clinical Research, and 7Research, ImClone Systems, New York, New York
Corresponding author
Wu, Yan
Venue
Clinical Cancer Research
Published
2010-02-15
Volume
16
Issue
4
Pages
1191-1205
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2148543405
Cited by
123
References
49
Citations by year
2026: 4 · 2025: 6 · 2024: 5 · 2023: 8 · 2022: 9 · 2021: 4 · 2020: 4 · 2019: 13 · 2018: 3 · 2017: 10 · 2016: 9 · 2015: 12 · 2014: 9 · 2013: 9 · 2012: 9
FWCI
3.51
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
University of Toronto
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
Keywords
TGFBR2, TGF-beta signaling, metastasis, primary tumor growth, antitumor immunity, tumor stroma, Smad2/3 signaling, tumor invasion, natural killer cells, cytotoxic T lymphocytes, neutralizing antibodies, tumor necrosis
MeSH terms
Receptor, Transforming Growth Factor-beta Type II, Animals, Antineoplastic Agents, Killer Cells, Natural, Mice, Inbred BALB C, Mice, Nude, Neoplasms, T-Lymphocytes, Cytotoxic, Protein Serine-Threonine Kinases, Receptors, Transforming Growth Factor beta, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Smad2 Protein, Antibodies, Neutralizing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-09-1634
The paper
Zhong, Z., Carroll, K. D., Policarpio, D., Osborn, C., Gregory, M., Bassi, R., Jimenez, X., Prewett, M., Liebisch, G., Persaud, K., Burtrum, D., Wang, S., Surguladze, D., Ng, S., Griffith, H., Balderes, P., Doody, J., Schwartz, J. D., Youssoufian, H., . . . Wu, Y. (2010). Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-09-1634

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.